Literature DB >> 8587409

Localization and characterization of endothelin-1 receptor binding in the blood vessels of human pulmonary tumors.

Y D Zhao1, D R Springall, Q Hamid, M Levene, J M Polak.   

Abstract

We have demonstrated endothelin-1 (ET-1) binding sites in the blood vessels of human pulmonary tumors by in vitro autoradiography. The blood vessels of the tumors were confirmed by immunostaining with von Willebrand factor. Specific [125I]ET-1 binding was identified in the blood vessels of all sizes in both tumor and stromal tissues. Nonspecific binding was observed in squamous cell carcinomas and in carcinoids. The ET-1 binding in blood vessels was specific, saturable, and time-dependent. The binding reached equilibrium at 120 min. Scatchard analysis of [125I]ET-1 binding to sections of blood vessels of squamous cell carcinoma indicated binding to a single class of binding sites, with a dissociation constant (Kd) of 0.16 nM and a maximal density of binding sites (Bmax) of 126 amol/mm2. The binding was competitively inhibited by ET-1 >> VIC > ET-2 > sarafotoxin (SRb) > ET-3 but not by other unrelated peptides. Our results provide evidence that ET-1 binding is localized in the blood vessels of pulmonary tumors and in stromal tissues surrounding the tumor nest. ET may play a role in the angiogenesis of tumor growth.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8587409

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  8 in total

Review 1.  Angiogenesis in cancer: the role of endothelin-1.

Authors:  K Dawas; M Loizidou; A Shankar; H Ali; I Taylor
Journal:  Ann R Coll Surg Engl       Date:  1999-09       Impact factor: 1.891

2.  Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.

Authors:  Snehal G Thakkar; Toni K Choueiri; Jorge A Garcia
Journal:  Curr Oncol Rep       Date:  2006-03       Impact factor: 5.075

3.  Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo.

Authors:  D Salani; G Taraboletti; L Rosanò; V Di Castro; P Borsotti; R Giavazzi; A Bagnato
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

4.  Role of endothelin-1 in neovascularization of ovarian carcinoma.

Authors:  D Salani; V Di Castro; M R Nicotra; L Rosanò; R Tecce; A Venuti; P G Natali; A Bagnato
Journal:  Am J Pathol       Date:  2000-11       Impact factor: 4.307

5.  Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.

Authors:  Sun-Jin Kim; Jang Seong Kim; Seung Wook Kim; Emily Brantley; Seok Joong Yun; Junqin He; Marva Maya; Fahao Zhang; Qiuyu Wu; François Lehembre; Urs Regenass; Isaiah J Fidler
Journal:  Neoplasia       Date:  2011-02       Impact factor: 5.715

6.  Endothelin-1 impairs angiogenesis in vitro through Rho-kinase activation after chronic intrauterine pulmonary hypertension in fetal sheep.

Authors:  Jason Gien; Nancy Tseng; Gregory Seedorf; Gates Roe; Steven H Abman
Journal:  Pediatr Res       Date:  2012-11-30       Impact factor: 3.756

Review 7.  Role of endothelin-1 in lung disease.

Authors:  K A Fagan; I F McMurtry; D M Rodman
Journal:  Respir Res       Date:  2001-02-22

8.  Dual ETA/ETB blockade with macitentan improves both vascular remodeling and angiogenesis in pulmonary arterial hypertension.

Authors:  Valerie Nadeau; Francois Potus; Olivier Boucherat; Renee Paradis; Eve Tremblay; Marc Iglarz; Roxane Paulin; Sebastien Bonnet; Steeve Provencher
Journal:  Pulm Circ       Date:  2017-10-24       Impact factor: 3.017

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.